Kancera AB (publ) announces that the results from the FRACTAL study will be presented at the European Society of Cardiology (ESC) annual conference on September 2, 2024.
Read MoreKancera AB (publ) today reports that the first part, phase Ib, has been successfully completed in the ongoing KANDOVA study, a combined phase Ib/IIa study of Kancera’s candidate drug KAND567 in ovarian cancer in combination with carboplatin. The objective...
Read MoreThe period in brief – financial summary for the first quarter 2024 Net sales amounted to SEK 0 million (SEK 0 million) R&D expenses amounted to SEK 11,4 million (SEK 15,2 million) Operating loss for the quarter amounted to...
Read MoreIn connection with the upcoming Interim Report for the first quarter 2024, Kancera AB (publ) provides an operational update regarding KANDOVA, a combined phase Ib/IIa study of KAND567 in ovarian cancer, and reports that: The patient recruitment pace has...
Read MoreKancera AB (publ) today announces that Robert Edfors is appointed as new Chief Scientific Officer and Senior Vice President Clinical Development and that the management team is extended with two new positions.
Read MoreKancera AB (publ) today reports positive results from the clinical phase I study with KAND145 in healthy subjects and that the primary objectives of the study were met: KAND145 is safe and tolerable at maximum exposure when administered as...
Read MoreThe board of directors of Kancera AB (”Kancera” or the ”Company”), hereby announces the outcome of the Company's rights issue of shares with preferential rights for the Company's existing shareholders and which was covered by subscription and guarantee commitments...
Read MoreKancera AB (”Kancera” or the ”Company”) announced on February 23, 2024, that the board of directors has resolved to carry out a new issue of shares with preferential rights for existing shareholders in the Company, corresponding to approximately SEK...
Read MoreThe board of directors of Kancera AB (”Kancera” or the ”Company”), has today, based on the issue authorization from the annual general meeting held on May 25, 2023, resolved on a new share issue with preferential rights for the...
Read MoreIn connection with the interim report for the fourth quarter 2023, Kancera AB (publ) today provides a general operational update and reports that the company has signed a license agreement with the University of Newcastle. Through this agreement, Kancera...
Read More